JANX Q4 2021 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

-$10M-591.2% margin

Operating Income

-$13M-834.8% margin

Net Income

-$13M-830.2% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+39.4%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$12M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$380M

Total Liabilities

$13M

Stockholders' Equity

$366M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	-$10M	$0	—
Operating Income	-$13M	-$2M	-715.1%
Net Income	-$13M	-$2M	-710.6%